Characterization of baboon class I major histocompatibility molecules: Implications for baboon-to-human xenotransplantation

Transplantation

Volumn 61, Issue 7, 1996, Pages 989-996

  Prilliman, Kiley ^a   Lawlor, David ^d   Ellexson, Mary ^a   Mcelwee, Norma ^a   Confer, Dennis ^b   Cooper, David K C ^c   Kennedy, Ronald C ^a   Hildebrand, William ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOTRANSPLANTATION; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BABOON; CONTROLLED STUDY; DNA POLYMORPHISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; XENOTRANSPLANTATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-A ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PAPIO; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029877308     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199604150-00001     Document Type: Article

References (52)

1. Giles GR, Boehmig HJ, Amemiya H, Halgrimson CG, Starzl TE. Clinical heterotransplantation of the liver. Transplant Proc 1970; 2: 506.
2. Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985; 254: 3321.
3. Auchincloss JH Jr. Xenogeneic transplantation. Transplantation 1988; 46: 1.
4. Chiche L, Adam R, Caillat-Zucman S, Castaing D, Bach JF, Bismuth H. Xenotransplantation: baboons as potential liver donors? Transplantation 1993; 55: 1418.
5. Starzl TE, Fung J, Tzakis A, et al. Baboon-to-human liver transplantation. Lancet 1993; 341: 65.
6. Fontes P, Rao AS, Ricordi C, et al. Human-to-baboon bone marrow transplantation after conditioning with nonlethal irradiation. Transplant Proc 1994; 26: 3367.
7. Starzl TE, Valdivia LA, Murase N, et al. The biological basis of and strategies for clinical xenotransplantation. Immunol Rev 1994; 141: 213.
8. Lehrman S. Baboon/man transplant backed for HIV victim. Nature 1995; 376: 204.
9. Hoke F. As cross-species transplantation forges ahead, some researchers call for caution. Scientist 1995; 9: 1.
10. Fox JL. Researchers consider cellular, solid-organ xenografts. ASM News 1995; 61: 453.
11. Nowak R. FDA puts the brakes on xenotransplants. Science 1995; 268: 630.
12. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207.
13. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1994; 15: 619.
14. Downie TR, Hows JM, Gore SM, Bradley BA, Howard MR. A survey of use of unrelated volunteer donor bone marrow transplantation at 46 centres worldwide, 1989-93. Bone Marrow Transplant 1995; 15: 499.
15. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988; 69: 239.
16. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 1988; 108: 806.
17. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
18. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874.
19. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273.
20. Theobald M. Allorecognition and graft-versus-host disease. Bone Marrow Transplant 1995; 15: 489.
21. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462.
22. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185.
23. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377.
24. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ. Bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591.
25. Townsend A, Bodmer H. Antigen recognition by class I restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601.
26. Bontrop RE, Jonker M. Conceptual aspects of antigen presentation across a species barrier. Transplant Proc 1993; 25: 86.
27. Hows JM, Bradley BA. The use of unrelated marrow donors for transplantation. Br J Haematol 1990; 76: 1.
28. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593.
29. Starzl TE, Tzakis A, Fung JJ, et al. Prospects of clinical xenotransplantation. Transplant Proc 1994; 26: 1082.
30. Rabin H, Neubauer RH, Hopkins RF III, Dzhikidze EK, Shevtsova ZV, Lapin BA. Transforming activity and antigenicity of an Epstein Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease. Intervirology 1977; 8: 240.
31. Miller MD, Lord CI, Stallard V, Mazzara GP, Letvin NL. The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques. J Immunol 1990; 144: 122.
32. Prilliman K, Steiner N, Ellexson M, et al. Novel alleles HLA-B*7802 and B*51022: Evidence for convergency in the HLA-B5 family. Tissue Antigens 1996; 47: 49.
33. Domena JD, Little A-M, Madrigal JA, et al. Structural heterogeneity in HLA-B70, a high frequency antigen of black populations. Tissue Antigens 1993; 42: 509.
34. Ennis PD, Zemmour J, Salter RD, Parham P. Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci USA 1990; 87: 2833.
35. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403.
36. Kumar S, Tamura K, Nei M. MEGA: molecular evolutionary genetics analysis, version 1.0. University Park, PA: The Pennsylvania State University, 1993.
37. Subbiah S, Harrison SC. A method for multiple sequence alignment with gaps. J Mol Biol 1989; 209: 539.
38. Watkins DI, Zemmour J, Parham P. Non-human primate MHC class I sequences, 1992. Immunogenetics 1993; 37: 317.
39. Parham P, Adams EJ, Arnett KL. The origins of HLA-A, B, and C polymorphism. Immunol Rev 1995; 143: 141.
40. Bjorkman PJ, Parham P. Structure, function and diversity of class I major histocompatibility molecules. Annu Rev Biochem 1990; 59: 253.
41. Moots RJ. In the groove: the fine detail of antigen presentation to cytotoxic T lymphocytes. Clin Sci 1993; 84: 585.
42. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 1991; 219: 277.
43. Rohren EM, Pease LR, Ploegh HL, Schumacher TNM. Polymorphisms in the pockets of major histocompatibility complex class I molecules influence peptide preference. J Exp Med 1993; 177: 1713.
44. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512.
45. Parham P, Belich M, Hildebrand WH, Little A-M, Madrigal JA, Zemmour J. W4.8. Correlation of serology with the structures of HLA class I molecules. In: Tsuji K, Aizawa M, Sasazuki T, eds. Proceedings of the eleventh international histocompatibility workshop and conference, Vol. 1. Oxford, UK: Oxford University Press, 1992: 542.
46. Inverardi L, Pardi R. Early events in cell-mediated recognition of vascularized xenografts: cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141: 71.
47. Newberg MH, Ridge JP, Vining DR, Salter RD, Engelhard VH. Species specificity in the interaction of CD8 with the α3 domain of MHC class I molecules. J Immunol 1992; 149: 136.
48. Smit JA, Stark JH, Myburgh JA. Improved technique for the mixed lymphocyte response in the Chacma baboon. Lab Animals 1988; 22: 212.
49. Stark JH, Smit JA, Neethling FA, Nortman PJ, Myburgh JA. Immunological compatibility between the Chacma baboon and man. Transplantation 1991; 52: 1072.
50. Platt JL. A perspective on xenograft rejection and accommodation. Immunol Rev 1994; 141: 127.
51. Brewer RJ, Del Rio MJ, Vaynblat M, et al. Adsorption of xenoantibodies for cardiac xenotransplantation in total lymphoid irradiation-treated baboons. Transplant Proc 1994; 26: 1355.
52. Stark JH, Smit JA, Botha JR, et al. Renal xenotransplantation of allosensitized patients: are baboon lymphocytes suitable cross-match targets? Transplant Proc 1994; 23: 1079.